Stocks and Investing
Stocks and Investing
Tue, September 26, 2017
Mon, September 25, 2017
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, September 22, 2017
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Do Kim Maintained (ALNY) at Buy with Increased Target to $134 on, Sep 22nd, 2017
Do Kim of BMO Capital, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Increased Target from $99 to $134 on, Sep 22nd, 2017.
Do has made no other calls on ALNY in the last 4 months.
There are 6 other peers that have a rating on ALNY. Out of the 6 peers that are also analyzing ALNY, 2 agree with Do's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $101 on, Thursday, September 21st, 2017
- Paul Matteis of "Leerink Swann" Maintained at Hold with Increased Target to $112 on, Thursday, September 21st, 2017
These are the ratings of the 4 analyists that currently disagree with Do
- Alan Carr of "Needham" Maintained at Strong Buy with Increased Target to $125 on, Thursday, September 21st, 2017
- Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $123 on, Thursday, September 21st, 2017
- Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $127 on, Thursday, September 21st, 2017
- Christopher Marai of "Nomura" Initiated at Sell and Held Target at $56 on, Friday, September 15th, 2017